In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
No. | 40 |
---|---|
Citation | J Thromb Haemost 16,p1580-1591(2018) |
Institute | Shire |
1st Author | R Hartmann |
AR | ○ |
PL | |
HD | |
Paper types | Basic science |
Main purpose | Drug efficacy evaluation |
Disease | Hemophilia A |
Antiplatelet drug | |
Anticoagulant drug | |
Other drug | emicizumab, aPCC, rFVIIa |
Clinical specimens | |
Animal | |
Keyword | Bispecific antibody |